Industry Intelligence
Healthcare companies developing biologics and medical countermeasures for radiation injury, immune dysregulation, complex conditions, and emergency preparedness.
Valion Bio says it has completed formulation work with Shear Kershman Laboratories on an oral mucosal version of Entolimod, which remains an investigational candidate for acute radiation syndrome.
Sunshine Biopharma announced pricing for a public offering comprising Common Units or Pre-Funded Units, with gross proceeds expected to be approximately $6.0 million before offering expenses.
Cosmos Health reported record preliminary revenue for the first nine months and third quarter of 2026, while cautioning that the figures remain unaudited and subject to review.
Lexaria Bioscience says its DehydraTECH oral-delivery platform is being evaluated for GLP-1 applications by the company and pharmaceutical industry partners.
Jaguar Health said family company Napo Pharmaceuticals will sponsor the 2nd Best of Elite Ped-GI meeting in Abu Dhabi and a panel on intestinal barriers beyond total parenteral nutrition.
NanoViricides said enrolment has begun in the Phase IIA portion of its NV-387 Oral Gummies trial, while DRC government data released on October 2, 2026, recorded 4,018 deaths and 8,300 confirmed cases in the outbreak.
Valion Bio says new Board Chair Thomas H. Jensen will work with management and the Board on execution around Entolimod, an investigational TLR5 agonist for acute radiation syndrome.
Utah Medical Products has extended the expiration date of its tender offer, giving stockholders additional time to consider the offer and the company’s scheduled calendar 3Q 2026 results.
Hypha Labs has outlined its developing Mushroom Accelerator platform, which the company says is designed to produce mushroom-derived biological material in approximately eight days.